Overview

The Maraviroc Central Nervous System (CNS) Study

Status:
Completed

Trial end date:
2011-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to describe the Central Nervous System exposure of maraviroc in HIV-1 infected subjects receiving a stable antiretroviral regimen, including maraviroc, at steady state.

Phase:

Phase 1

Details

Lead Sponsor:

Imperial College London

Collaborator:

Pfizer

Treatments:

Maraviroc